Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ZV0710BE |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population receiving 90Y-Zevalin, with model-predicted data at reimbursement on the basis of a clinical trial in heavily pre-treated NHL.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Group 1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| [90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128) | Drug | Zevalin was administered according to the directives in the approved package leaflet. |
|
| Measure | Description | Time Frame |
|---|---|---|
| The medical resources consumed due to hematological adverse events that occurred following treatment with 90Y-Zevalin treatment | one year after inclusion |
| Measure | Description | Time Frame |
|---|---|---|
| the health related quality of life prior to and following treatment (using EQ-5D and FACT-LYM) | baseline: before 1st administration, 8 days after baseline, 1, 2 & 3 months after baseline | |
| the clinical outcomes (survival status, response status), TTNT (time to next treatment) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All patients with relapsed or refractory FL who have been treated with 90Y-Zevalin in Belgium within the first 24 months after ethics approval
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Many Locations | Belgium |
Not provided
Not provided
Not provided
Not provided
| 1 year |
| ID | Term |
|---|---|
| D008224 | Lymphoma, Follicular |
| D008228 | Lymphoma, Non-Hodgkin |
| ID | Term |
|---|---|
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C422802 | ibritumomab tiuxetan |
Not provided
Not provided
Not provided